The ACT4 ALS-MND centers

CHU de Montpellier

Dr Florence Esselin : Responsable du centre SLA

ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis (Recruiting)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

80 avenue Augstin Fliche
34090 Montpellier
France

CHU de Nancy

Dr Sophie Pittion-Vouyovitch : Responsable du Centre SLA

AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
TRIALS // Treatment Combining Riluzole and IFB-088 in Bulbar ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)

Hôpital Central
29 Avenue du Maréchal de Lattre de Tassigny CO n°34
54035 Nancy Cedex
France

CHU de Nice

Dr Marie-Hélène Soriani : Responsable du Centre SLA

ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS (Completed)
TRIALS // Treatment Combining Riluzole and IFB-088 in Bulbar ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis (Recruiting)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

Hôpital Pasteur
30 Avenue de la Voie Romaine
06001 Nice Cedex 1
France

CHU de Rennes

Pr Paul Sauleau

2 rue Henri le Guilloux
35033 Rennes
France

CHU de Saint-Etienne

Pr Jean-Philippe Camdessanché : Responsable du Centre SLA

Hôpital Nord
42055 Saint-Etienne Cedex 2
France

CHU de Strasbourg

Dr Marie-Céline Fleury : Responsable du Centre SLA

Hôpital de Hautepierre
Avenue Molière
67200 Strasbourg
France

CHU de Toulouse

Dr Pascal Cintas : Responsable du Centre SLA

Hôpital Pierre Paul Riquet
31059 Toulouse Cedex
France

CHU de Tours

Pr Philippe Corcia : Responsable du Centre SLA, Coordonnateur du réseau ACT4ALS-MND

ReALiSe // A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants with Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
TRIALS // Treatment Combining Riluzole and IFB-088 in Bulbar ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS (Completed)
FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis (Recruiting)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

CHU Bretonneau
2 Boulevard TONNELLE
37044 Tours CEDEX 9
France

Lille University Hospital

Dr Véronique Danel : Head of the ALS Centre of Lille // Prof David Devos : Coordinator of the ACT4ALS-MND network

ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
AB19001 // Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (Suspended recruitment)
CARDINALS // Study to Assess the Effects of PTC857 Treatment in Participants With ALS (Completed)
IASO // Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With ALS (Completed)
TRIALS // Treatment Combining Riluzole and IFB-088 in Bulbar ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis (Recruiting)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

2 Av. Oscar Lambret
59000 LILLE
France

Paris University Hospital

Dr François Salachas : Paris ALS center Head // Prof Gaëlle Bruneteau : ACT4ALS-MND Coordinator

ReALiSe // A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants with Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
ASTRALS // A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (Follow-Up (recruiting ended))
SEALS // A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c. (Follow-Up (recruiting ended))
ALS-Gut // Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association with Clinical Phenotypes (Coming soon)
ATLAS // A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (Follow-Up (recruiting ended))
DAZALS // Dazucorilant in Patients With ALS (Active not recruiting)
IASO // Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With ALS (Completed)
PHOENIX // Trial of AMX0035 for ALS Treatment (Completed)
ADORE // Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With ALS (Completed)
FILSLAN-NF // Neurofilament Assay for the Diagnosis of ALS (Completed)
FG-CoALS // Franco-German cohort study to determine factors associated with weight loss in amyotrophic lateral sclerosis (Recruiting)
RNALS // ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach (Recruiting)

Hôpital Pitié Salpêtrière
47-83 Bd de l'Hôpital
75013 PARIS
France